NCT00784212

Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy

A Multicenter, Single-blind, Within-subject, Placebo-controlled Proof of Concept Study to Assess the Effect of Single Oral Doses of BGG492 on the Photoparoxysmal EEG Response in Patients With Photosensitive Epilepsy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the efficacy of BGG492 in reducing the sensitivity to flashing lights of patients with photosensitive epilepsy, using EEG as a readout.

Conditions

• Photosensitive Epilepsy

Interventions

Type	Name	Description
DRUG	BGG492
DRUG	BGG492
DRUG	Placebo

Timeline

• Start date: 2008-10-01
• Primary completion: 2010-09-01
• Completion: 2010-09-01
• First posted: 2008-11-03
• Last updated: 2016-09-23

Locations

4 sites across 1 country: Germany